CLOUDBREAK-B Achieves Over 70% Growth in 6 Days as Core Product CBT-009 Obtains Patents in Japan and Europe
Stock Performance: CLOUDBREAK-B (02592.HK) has seen a significant increase in its stock price, rising 12.26% to $8.15, with a trading volume of over 3 million shares, marking a 73.4% increase from last Thursday's closing price of $4.7.
Patent Grants: The Group's US subsidiary, ADS USA, has received patent grants for its core product, CBT-009, from both the Japan Patent Office and the European Patent Office.
Collaboration Opportunities: The company anticipates initiating collaborations with major pharmaceutical firms to establish licensing agreements for the development and distribution of CBT-009 in Japan and Europe.
Product Information: CBT-009 is a new ophthalmic formulation of atropine aimed at treating juvenile myopia in children and adolescents aged 5 to 19 years.
Trade with 70% Backtested Accuracy
Analyst Views on 02592
No data
About the author
CLOUDBREAK-B Achieves Over 70% Growth in 6 Days as Core Product CBT-009 Obtains Patents in Japan and Europe
Stock Performance: CLOUDBREAK-B (02592.HK) has seen a significant increase in its stock price, rising 12.26% to $8.15, with a trading volume of over 3 million shares, marking a 73.4% increase from last Thursday's closing price of $4.7.
Patent Grants: The Group's US subsidiary, ADS USA, has received patent grants for its core product, CBT-009, from both the Japan Patent Office and the European Patent Office.
Collaboration Opportunities: The company anticipates initiating collaborations with major pharmaceutical firms to establish licensing agreements for the development and distribution of CBT-009 in Japan and Europe.
Product Information: CBT-009 is a new ophthalmic formulation of atropine aimed at treating juvenile myopia in children and adolescents aged 5 to 19 years.
CLOUDBREAK-B Achieves Over 70% Growth in 6 Days as Core Product CBT-009 Obtains Patents in Japan and Europe
Stock Performance: CLOUDBREAK-B (02592.HK) has seen a significant increase in its stock price, rising 12.26% to $8.15, with a trading volume of over 3 million shares, marking a 73.4% increase from last Thursday's closing price of $4.7.
Patent Grants: The Group's US subsidiary, ADS USA, has received patent grants for its core product, CBT-009, from both the Japan Patent Office and the European Patent Office.
Collaboration Opportunities: The company anticipates initiating collaborations with major pharmaceutical firms to establish licensing agreements for the development and distribution of CBT-009 in Japan and Europe.
Product Information: CBT-009 is a new ophthalmic formulation of atropine aimed at treating juvenile myopia in children and adolescents aged 5 to 19 years.
